Skip to main content
Notice2022-08452

The Use of Published Literature in Support of New Animal Drug Applications; Draft Guidance for Industry; Availability

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
April 20, 2022

Issuing agencies

Health and Human Services DepartmentFood and Drug Administration

Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry #106 entitled "The Use of Published Literature in Support of New Animal Drug Applications." This draft guidance, when finalized, will replace the existing final guidance #106, "The Use of Published Literature in Support of New Animal Drug Approval," which FDA published in August 2000 and which specifically addressed the use of a single article to support drug approval. This revision of the guidance document considers multiple uses of the scientific literature, including narrative reviews, systematic reviews, and meta-analyses to support approval of a new animal drug.

Indexed from Federal Register on April 20, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.